DPP生活方式与二甲双胍干预对骨密度的长期影响
在糖尿病高危人群中,DPP研究随机分配至强化生活方式干预或二甲双胍,均伴随体重下降;DPPOS随访约16年后,与安慰剂组相比,两组股骨颈骨密度无显著差异,骨质疏松患病率低且组间相似,提示长期无负性影响,二甲双胍潜在正性作用待研究。
要点
- DPP随机至生活方式干预或二甲双胍未对骨密度造成长期负性影响。
- 随访第12年股骨颈骨密度组间差异均无统计学意义。
- 骨质疏松患病率低且组间相似,二甲双胍对骨潜在正性作用待研究。
核心结论
- 在糖尿病高危队列中,生活方式干预或二甲双胍未对骨密度产生长期负性影响。
- 二甲双胍对骨的潜在正性作用值得进一步研究。
研究设计与样本
- DPP研究将3234名糖尿病高危参与者随机分配至强化生活方式干预、二甲双胍或安慰剂。
- DPPOS随访中2779人继续参与,第12年时1367人接受双能X线吸收法骨密度扫描。
- 采用性别特异性线性回归模型比较组间骨密度,校正年龄、种族/民族、DPP基线体重和负重活动。
主要发现
- DPPOS第12年时平均年龄66.5(±9.5)岁。
- 男性股骨颈骨密度生活方式干预组与安慰剂组差异为-0.021 g/cm2(95%CI -0.063至0.021),女性为+0.014 g/cm2(95%CI -0.014至0.042)。
- 男性二甲双胍组与安慰剂组股骨颈骨密度差异为+0.017 g/cm2(95%CI -0.023至0.058),女性为+0.019 g/cm2(95%CI -0.009至0.047),均无统计学差异。
- 骨质疏松患病率男性为0.9%(p=0.745),女性为2.4%(p=0.466),各组相似且低。
关键数值与推荐
- 男性股骨颈骨密度生活方式干预与安慰剂差异-0.021 g/cm2(95%CI -0.063至0.021)。
- 女性股骨颈骨密度生活方式干预与安慰剂差异+0.014 g/cm2(95%CI -0.014至0.042)。
- 男性股骨颈骨密度二甲双胍与安慰剂差异+0.017 g/cm2(95%CI -0.023至0.058)。
- 女性股骨颈骨密度二甲双胍与安慰剂差异+0.019 g/cm2(95%CI -0.009至0.047)。
- 骨质疏松患病率男性0.9%(p=0.745),女性2.4%(p=0.466)。
临床怎么用
- 对糖尿病高危患者,生活方式干预或二甲双胍治疗无需担心长期骨密度负性影响。
- 二甲双胍对骨密度的潜在正性作用尚需进一步研究,暂不作为骨保护推荐依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: In the Diabetes Prevention Program Outcome Study (DPPOS), a cohort at high risk of diabetes, randomization to intensive lifestyle intervention or metformin, both associated with weight loss, did not have long-term negative effects on BMD compared with the placebo group. Potential positive effects of metformin on bone warrant further investigation. INTRODUCTION: Randomization to lifestyle intervention (ILS) or metformin in the Diabetes Prevention Program (DPP) resulted in weight loss and reduced progression to diabetes. Weight loss is associated with reduced bone mineral density (BMD), but the long-term effects of these interventions on BMD are unknown. In the DPP Outcome Study (DPPOS), we determined if randomization to ILS or metformin, compared with placebo, was associated with differences in BMD approximately 16 years later. METHODS: Of 3234 DPP participants, 2779 continued in DPPOS and were offered ILS in group format. Those randomized to metformin were offered unmasked metformin. At DPPOS year 12, 1367 participants had dual-energy X-ray absorptiometry scans. BMD in metformin and ILS groups was compared to placebo using sex-specific linear regression models, adjusted for age, race/ethnicity, and weight and weight-bearing activity at DPP baseline. RESULTS: At DPPOS year 12, mean age was 66.5 (±9.5) years. Femoral neck BMD was similar in the ILS and placebo groups in men (difference = -0.021 g/cm2, 95%CI (-0.063, 0.021)) and in women (+0.014 g/cm2, 95%CI (-0.014, 0.042)). Femoral neck BMD was higher in the metformin compared to placebo group although not statistically different in men (+0.017 g/cm2, 95% CI (-0.023, 0.058)) and in women (+0.019 g/cm2, 95% CI (-0.009, 0.047)). Prevalence of osteoporosis was low and similar across treatment groups in men (0.9%; p=0.745) and women (2.4%; p=0.466). CONCLUSION: In a cohort at high risk of diabetes, lifestyle intervention or metformin did not appear to have long-term negative effects on BMD. Potential positive effects of metformin on bone warrant further research.
引用
- Schwartz AV, Pan Q, Aroda VR, et al. Long-term effects of lifestyle and metformin interventions in DPP on bone density. Osteoporos Int. 2021. PMID: 34086101. doi:10.1007/s00198-021-05989-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。